Janus Henderson Group
RPRX icon

Janus Henderson Group’s Royalty Pharma RPRX Stock Holding History

Janus Henderson Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.28M Sell
47,589
-177
-0.4% -$7.75K ﹤0.01% 1285
2025
Q4 		$1.85M Buy
47,766
+14,377
+43% +$548K ﹤0.01% 1381
2025
Q3 		$1.18M Hold
33,389
– – ﹤0.01% 1576
2025
Q2 		$1.2M Sell
33,389
-848
-2% -$28.1K ﹤0.01% 1528
2025
Q1 		$1.07M Hold
34,237
– – ﹤0.01% 1586
2024
Q4 		$873K Sell
34,237
-1,729,008
-98% -$45.8M ﹤0.01% 1761
2024
Q3 		$49.9M Sell
1,763,245
-4,172
-0.2% -$116K 0.03% 390
2024
Q2 		$46.6M Sell
1,767,417
-85,243
-5% -$2.36M 0.03% 394
2024
Q1 		$56.3M Sell
1,852,660
-47,954
-3% -$1.41M 0.03% 369
2023
Q4 		$53.4M Sell
1,900,614
-335,782
-15% -$9.23M 0.03% 361
2023
Q3 		$60.7M Sell
2,236,396
-37,704
-2% -$1.12M 0.04% 333
2023
Q2 		$69.9M Sell
2,274,100
-289,895
-11% -$9.82M 0.04% 322
2023
Q1 		$92.4M Sell
2,563,995
-36,506
-1% -$1.35M 0.06% 264
2022
Q4 		$103M Sell
2,600,501
-2,927,661
-53% -$122M 0.07% 237
2022
Q3 		$222M Buy
5,528,162
+2,421,561
+78% +$103M 0.08% 221
2022
Q2 		$131M Buy
3,106,601
+323,775
+12% +$13.3M 0.09% 217
2022
Q1 		$108M Buy
2,782,826
+212,647
+8% +$8.35M 0.05% 298
2021
Q4 		$102M Buy
2,570,179
+207,885
+9% +$8.08M 0.04% 352
2021
Q3 		$85.4M Sell
2,362,294
-1,383,120
-37% -$53.7M 0.04% 391
2021
Q2 		$154M Buy
3,745,414
+2,505,360
+202% +$107M 0.07% 290
2021
Q1 		$54.1M Sell
1,240,054
-3,661,646
-75% -$174M 0.02% 529
2020
Q4 		$245M Buy
4,901,700
+177,056
+4% +$7.51M 0.11% 192
2020
Q3 		$199M Buy
4,724,644
+217,506
+5% +$9.33M 0.1% 202
2020
Q2 		$219M Buy
+4,507,138
New +$223M 0.12% 180

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group's RPRX Position: Q1 2026 in Review

Janus Henderson Group reduced its Royalty Pharma (RPRX) stake by 0.37% in Q1 2026, selling an estimated $7.75K and leaving 47,589 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1285.

Janus Henderson Group first reported a position in RPRX in Q2 2020 and has held it in 24 quarters since. The position peaked at $245M in Q4 2020. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Janus Henderson Group held 47,589 shares of Royalty Pharma worth $2.28M as of Q1 2026.
  • Janus Henderson Group sold 177 Royalty Pharma shares in Q1 2026, an estimated $7.75K.
  • Royalty Pharma made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1285 holding.
  • Janus Henderson Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 24 quarters since.
  • Janus Henderson Group's Royalty Pharma position peaked at $245M in Q4 2020.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.